 |
인쇄하기
취소
|
Indian generic giants to get easier access to Korean pharmaceutical market
Influenced by the government’s firm determination to stamp out illegal rebate here, Indian generic markers are poised to enter the Korean pharmaceutical market as situation will permit.
"If Cipla makes good business success in Korea with more than 100 generic products, other top generic drug companies of India like Ranbaxy and Drs. Reddy will follow the suit,” a market insider said.
“If t...
"If Cipla makes good business success in Korea with more than 100 generic products, other top generic drug companies of India like Ranbaxy and Drs. Reddy will follow the suit,” a market insider said.
“If t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.